REDWOOD CITY, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), a commercial-stage biopharmaceutical company focused on the research, development and commercialization of ...
RESULTS: One dose of pegfilgrastim per chemotherapy cycle was comparable to daily subcutaneous injections of filgrastim with regard to all efficacy end points, including the duration of severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results